Engineered immune cells take on Hard-to-Treat blood cancers
NCT ID NCT07584889
First seen May 15, 2026 · Last updated May 15, 2026
Summary
This study tests a new type of immune cell therapy (CD19-CAR.p40-T) for people with blood cancers like lymphoma and leukemia that have come back or not responded to treatment. About 10 adults will receive their own immune cells that have been modified to better find and attack cancer cells. The goal is to see if this approach is safe and can help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shenzhen University General Hospital
RECRUITINGShenzhen, Other (Non U.s.), 518055, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.